๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 21 Shanghai 15 Hangzhou 8 Fuzhou 6 Chongqing 5
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing21 Shanghai15 Hangzhou8 Fuzhou6 Chongqing5
All 27 locations
Target enrolment
to

Trials with a site in Beijing

21 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study of IBI3046 in Participants With Overweight or Obesity
NCT07809945Obesity and Overweight
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
128
Beijing
2026-09-15
Recruiting
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
NCT07793019Overweight, Healthy Participants, Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
104
Beijing
2026-09-07
Not yet open
A Open-Label Phase in Participants With Multiple Myeloma
NCT07764861Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
120
Beijing
2026-08-15
Not yet open
Study of IBI3016 in People With Mild or Moderate Hypertension Patients
NCT07556796Hypertension
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
30
Beijing
2026-05-15
Recruiting
IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07483567CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
90
Beijing
2026-04-17
Active, closed
IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
NCT07473960Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
198
Beijing
2026-04-01
Recruiting
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
NCT07399067Atopic Dermatitis
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
120
Beijing
2026-02-06
Not yet open
A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients
NCT07352969Hypertension
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
352
Beijing
2026-02-06
Not yet open
IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
NCT07402070Resectable Stage II-III Non-small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
10
Beijing
2026-02-04
Recruiting
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
NCT07330934Atopic Dermatitis
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
403
Beijing
2025-12-31
Recruiting
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
NCT06937749Metabolic Dysfunction-associated Steatohepatitis (MASH)
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
165
Beijing
2025-07-01
Recruiting
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMIโ‰ฅ28 kg/m2
NCT06931028Sleep Apnea, Obstructive, Obesity
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
260
Beijing
2025-06-12
Active, closed
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease ๏ผˆMAFLD๏ผ‰
NCT06884293Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
479
Beijing
2025-05-09
Recruiting
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
NCT06862908Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
141
Beijing
2025-04-01
Recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
NCT06797297Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-02-24
Recruiting
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
NCT06349408Locally Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
250
Beijing, Shanghai, Hangzhou
2025-01-10
Recruiting
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06083207Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
116
Beijing, Nanning, Wuhan, Nanjing, Suzhou, Xuzhou, Nanchang, Shanghai
2024-07-29
Active, closed
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
464
Bengbu, Hefei, Lu'an, Wuhu, Beijing, Fuzhou, Lanzhou, Dongguan
2024-06-30
Recruiting
A Study of IBI363 in Subjects With Advanced Melanoma
NCT06081920Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Beijing, Fuzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Changchun, Jinan
2023-10-19
Recruiting
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
NCT05636215Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
368
Beijing, Chongqing
2023-04-04
Recruiting
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
NCT05458219Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
470
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha
2022-10-26
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

13 of the 21 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 21 studies
PhaseStudiesRecruitingShare
Phase 210747.6%
Phase 15323.8%
Phase 34119%
Phase 1/2229.5%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Innovent Biologics (Suzhou) Co. Ltd.2113
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.